Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The purpose of this study is to determine whether continued administration of Drotrecogin Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion period - results in a more rapid resolution of hypotension in severe septic patients.
Epistemonikos ID: 115f4dd45bbe30d3e6c3cd463468e07045fef122
First added on: May 04, 2024